Please enable JS


Positive topline results were announced from the phase 2 LADDER study evaluating the efficacy and safety of its investigational Port Delivery System (PDS) with ranibizumab in people with wet age-related macular degeneration (AMD).

In the study, it was reported that a majority of patients were able to go 6 months or longer between their initial implant and their first refill of the device, and in the highest dose of the study, 80% of patients went 6 months or longer. The small, refillable eye implant, which is slightly longer than a grain of rice, is designed to allow people with wet AMD to go several months without needing to visit their ophthalmologist for treatment.

For more information :